S. Gordon

Cryptogenic liver disease in the United States: further evidence for non-A, non-B, and non-C hepatitis.

V P Kodali, S. Gordon, A L Silverman et al. · PubMed · 1994 · 102 citations

751 The safety and efficacy of viramidine® plus pegylated interferon alpha-2B versus ribavirin plus pegylated interferon alpha-2B in therapy-naïve patients infected with HCV: Phase 3 results

Y. Benhamou, Paul J. Pockros, M. Rodrieuez-Torres et al. · Journal of Hepatology · 2006 · 52 citations

Viral Hepatitis, Immunology, Antiviral Drug Development +9

104 BOCEPREVIR (B) COMBINATION THERAPY IN NULL RESPONDERS (NR): RESPONSE DEPENDENT ON INTERFERON RESPONSIVENESS

E. Schiff, F. Poordad, Ira M. Jacobson et al. · Journal of Hepatology · 2008 · 49 citations

Immunology, Antiviral Response, Antiviral Drug Development +6

1360 PEGYLATED INTERFERON-LAMBDA (PEGIFN-λ) SHOWS SUPERIOR VIRAL RESPONSE WITH IMPROVED SAFETY AND TOLERABILITY VERSUS PEGIFNα-2A IN HCV PATIENTS (Gl/2/3/4): EMERGE PHASE IIB THROUGH WEEK 12

Stefan Zeuzem, S. Arora, B. Bacon et al. · Journal of Hepatology · 2011 · 46 citations

Viral Persistence, Viral Hepatitis, Immunodeficiencies +10

Epidemiology of hepatitis C virus infection in a suburban Detroit community.

Ronald A. Meyer, S. Gordon · PubMed · 1991 · 32 citations

Hepatitis B, Pathology, Cirrhosis +20